公开(公告)号：US20220313803A1

公开(公告)日：2022-10-06

申请号：US17420963

申请日：2020-01-06

Applicant: BRIGHTPATH BIOTHERAPEUTICS CO., LTD.

Inventor： Tetsuro SASADA ,  Junya OHTAKE ,  Susumu IIZUMI ,  Norihiro NAKAMURA ,  Fumiko ISODA ,  Kazuhiko ODAKA

IPC: A61K39/00 ,  A61P35/00 ,  A61K35/17

Abstract: Problem to be solved: An object of the present invention is to obtain medicinal effect that could not be obtained by conventional peptide vaccines that activate and proliferate a CD8-positive CTL by administering a Class II epitope as a peptide vaccine. Solution: The inventors of the present invention have found, as a result of diligent examination on the aforementioned problems, that these problems can be solved by acquiring a peptide having a partial amino acid sequence containing a mutated amino acid of a neoantigen expressed in cancer cells and being an epitope presented by a Class II molecule.

公开(公告)号：US20230210967A1

公开(公告)日：2023-07-06

申请号：US17996866

申请日：2021-04-21

Applicant: BRIGHTPATH BIOTHERAPEUTICS CO., LTD. ,  KAGOSHIMA UNIVERSITY

Inventor： Yukie SASAKURA ,  Norihiro NAKAMURA ,  Yuji MISHIMA ,  Noriko MATSUMOTO ,  Fumiko ISODA ,  Yuji ITO

IPC: A61K39/00 ,  A61K39/12 ,  A61K47/64 ,  A61K47/68 ,  A61P35/00

CPC classification number: A61K39/0011 ,  A61K39/12 ,  A61K47/64 ,  A61K47/68 ,  A61P35/00 ,  A61K2039/505 ,  A61K2039/5154

Abstract: A peptide vaccine complexed so that the peptide vaccine can be delivered specifically to the surface of specific immune cells and a method for delivering a peptide vaccine specifically to the surface of specific immune cells. The peptide vaccine is combined with an IgG binding peptide capable of binding to an IgG that is an agonist against molecules on the surface of specific immune cells such as dendritic cells.

公开(公告)号：US20240391997A1

公开(公告)日：2024-11-28

申请号：US18579286

申请日：2022-07-15

Applicant: BRIGHTPATH BIOTHERAPEUTICS CO., LTD.

Inventor： Kanto Nakajima ,  Mamoru Shiraishi ,  Takahiko Aramaki ,  Haruka Matsumura ,  Noriko Matsumoto

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

Abstract: An antibody or an antibody derivative with enhanced functionality targeting the Tim-3 antigen. The antibody binds to the Tim-3 antigen, has complementary determining regions in the heavy and light chains with specific amino acid sequences, and can activate T cells with cytotoxic effects against cancer cells.

公开(公告)号：US20230321241A1

公开(公告)日：2023-10-12

申请号：US18018380

申请日：2021-07-28

Applicant: BrightPath Biotherapeutics Co., Ltd.

Inventor： Kazuhiko ODAKA

IPC: A61K39/00 ,  A61K39/395 ,  A61P37/04 ,  A61K9/19

CPC classification number: A61K39/4634 ,  A61K39/3955 ,  A61P37/04 ,  A61K9/19 ,  A61K2039/505

Abstract: The present disclosure comprises a cancer peptide vaccine comprising a peptide of Asn-Val-Leu-His-Phe-Phe-Asn-Ala-Pro-Leu (SEQ ID NO: 1), a peptide of Ala-Ser-Leu-Asp-Ser-Asp-Pro-Trp-Val (SEQ ID NO: 2), a peptide of Lys-Leu-Lys-His-Tyr-Gly-Pro-Gly-Trp-Val (SEQ ID NO: 3), and a peptide of Leu-Leu-Gln-Ala-Glu-Ala-Pro-Arg-Leu (SEQ ID NO: 4), and a method of preparing the same.

公开(公告)号：US20230220104A1

公开(公告)日：2023-07-13

申请号：US18000064

申请日：2021-05-28

Applicant: BRIGHTPATH BIOTHERAPEUTICS CO., LTD.

Inventor： Norihiro NAKAMURA ,  Risa NOZAWA ,  Toshifumi OBONAI ,  Haruka BAN ,  Yukie SASAKURA ,  Yuji MISHIMA ,  Noriko MATUMOTO

IPC: C07K16/28 ,  C07K16/40 ,  A61P35/00 ,  G01N33/50

CPC classification number: C07K16/2896 ,  C07K16/40 ,  A61P35/00 ,  G01N33/5011 ,  C07K2317/565 ,  A61K2039/505

Abstract: An antibody having a higher function targeting a CD73 antigen, and more specifically, an antibody for cancer treatment having a higher activity. The antibody or a human-type antibody derivative that has a binding activity to a CD73 antigen and activates T cells having a toxic activity to cancer cells, and includes complementarity determining regions of any combination of heavy and light chains each having a specific amino acid sequence.

公开(公告)号：US20220265714A1

公开(公告)日：2022-08-25

申请号：US17626345

申请日：2020-07-30

Applicant: SHINSHU UNIVERSITY ,  KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION ,  BrightPath Biotherapeutics Co., Ltd.

Inventor： Yozo Nakazawa ,  Shigeki YAGYU ,  Miyuki TANAKA ,  Kayoko NAKAMURA ,  Masahiro OKADA ,  Makoto KONDO ,  Tomokuni SHIGEURA ,  Shogo HIROTA

IPC: A61K35/17 ,  C12N5/0783 ,  A61P35/00 ,  C07K14/715 ,  C07K14/705 ,  C07K16/32

Abstract: The present disclosure includes a method of producing a cell population containing Chimeric Antigen Receptor (CAR)-expressing immune cells, comprising co-culturing CAR-expressing immune cells and cells expressing a target antigen of the CAR, wherein the CAR-expressing immune cells are cells into which a CAR gene has been introduced and the target antigen-expressing cells are normal blood cells that have been engineered to express the target antigen.